K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$1.73
Prev. Close
$2.05
Prev. Day's Range
$1.72 - $2.14
52W Range
$1.66 - $4.94
Trading Volume
752.477K
MC
$102.135M
P/E Ratio
--
EPS
$-1.10
Company Overview
NASDAQ
Rapid Micro Biosystems Inc (RPID) is a pioneering biotechnology company dedicated to transforming microbiological quality control in the pharmaceutical and biotechnology sectors. By leveraging advanced automated growth-based microbial detection technologies, RPID enhances the accuracy and efficiency of microbial testing, which is critical for compliance with rigorous regulatory standards. With the increasing demand for rapid and effective quality assurance solutions, Rapid Micro is strategically positioned to lead innovations in testing methodologies, ensuring product safety and integrity in highly regulated environments.
SectorHEALTHCARE
IndustryMEDICAL DEVICES
Headquarters25 HARTWELL AVENUE, LEXINGTON, MA, UNITED STATES, 02421
RPID focuses on the development and commercialization of 3D bioprinting technologies for regenerative medicine applications. The company aims to address critical challenges in tissue engineering and organ transplantation using innovative bioprinting solutions.
RPID operates in the healthcare sector within the biotechnology industry. Its primary focus is on leveraging advanced bioprinting technologies for medical and research applications.
RPID generates revenue through the sale of its proprietary 3D bioprinting equipment, related consumables, and collaborations or licensing agreements with research institutions and healthcare companies. Expanding market adoption of regenerative medicine solutions is a key revenue driver.
RPID faces competition from other biotechnology companies developing solutions for tissue engineering and organ regeneration. Key competitors include firms specializing in bioprinting, regenerative medicine, and advanced biomaterials.
Investing in RPID carries risks, including potential delays in regulatory approval, competition from alternative medical technologies, and reliance on research and development milestones. Furthermore, fluctuations in funding or adoption of bioprinting technologies could impact business performance.
Currently, RPID does not pay dividends, as the company is focused on reinvesting earnings into research and development to support growth and innovation in its bioprinting technologies.
RPID has significant growth opportunities in areas like organ transplantation, personalized medicine, and regenerative therapies. Advances in bioprinting technology and increasing demand for alternatives to traditional organ donation could further drive business success.
Investors can evaluate RPID's performance by analyzing its revenue growth, progress in research and development, product licensing agreements, and adoption of bioprinting in the healthcare market. Additionally, closely monitoring industry trends and regulatory developments is essential for assessing potential growth.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
